120 likes | 207 Vues
Agenda. Overview of clinical “pull” What is the overall aim? What are the research challenges?. Ultra-Precise Radiotherapy - Cyberknife. Precise Radiotherapy Target radioresistant regions? hypoxic (oxygen-starved) sections of a tumour. But Hypoxic regions are not static
E N D
Agenda • Overview of clinical “pull” • What is the overall aim? • What are the research challenges?
Ultra-Precise Radiotherapy - Cyberknife • Precise Radiotherapy • Target radioresistant regions? • hypoxic (oxygen-starved) sections of a tumour. • But • Hypoxic regions are not static • Imaging (eg CT) is a snapshot • Also – can we measure cancercell kill? • Implanted sensing … • Ian, David
Real Time Tumour Monitoring Miniaturised sensors pH, T, O2, conductivity Implant sensorssurgically into the tumour microenvironment before radiotherapy Sensor chip around 7mmx500μmx500μm … the size of a grass seed
Sensors and Therapy A group of cancer cells
Sensors and Therapy RT-Resistant (1) and RT-sensitive cells (2) and other stuff (3, 4)
Sensors and Therapy Insert chips
Sensors and Therapy Chips detect and signal RT-resistant zones
Sensors and Therapy Deliver extra RT dose to resistant zones
More “direct” measures than O2? • Caspases • “the executioners of cell death” • Hypoxia Inducible Factor (HIF) • Ian/David (why?) • Mark/Andy (how?)
Target radiotherapy sensor chip powered down Find radio-resistant regions Measure cancer cell kill Sensors and Therapy Implant sensors in vivo
Implications – Personalised Therapy • Improved targetting of radiotherapy • Different scheduling strategy • Improved cure rates for many solid cancers • Potential for implanted, local chemotherapy • Major change to NHS practice • Regulation? Acceptability? Value Systems? • Joyce
Social Sciences JoyceTait Implantable Microsystems for Personalised Anti-Cancer Therapy (IMPACT) Engineering Alan Murray, Anthony Walton, Steve McLaughlin Chemistry Mark Bradley Cancer Medicine Ian Kunkler Veterinary Medicine David Argyle